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Introduction: Information on treatment outcomes with interferon plus ribavirin combination therapy in
chronic hepatitis C patients with normal alanine aminotransaminase (ALT) levels is limited.
Aim: The aims of this study were to assess outcomes of treatment with interferon plus ribavirin in patients
with normal ALT levels (normal ALT group, n = 52) compared with those with elevated ALT levels (raised
ALT group, n = 53), and to document the rate at which patients with normal ALT levels have an apparent
worsening of disease, as shown by increases in ALT levels.
Results: At the end of treatment (week 48), 31 patients (59.6%) in the normal ALT group and 30 patients
(56.6%) in the raised ALT group had undetectable hepatitis C virus (HCV) RNA (p = 0.75). A sustained
virological response (SVR) was achieved in 20 patients (38.5%) in the normal ALT group and in 21
patients (39.6%) in the raised ALT group (p = 0.90). Patients were subsequently followed up for a median
of 29.8 (interquartile range 25th–75th percentile (IQR) 20.8–36.2) months in the normal ALT group and
for a median of 26.1 (IQR 17.7–36.3) months in the raised group (p = 0.20) after week 72 of treatment.
Among patients without SVR in the normal ALT group, only three patients (9.4%) developed persistently
raised ALT levels following therapy.
Conclusions: Combination therapy with interferon plus ribavirin is associated with a similar SVR in patients
with normal ALT levels compared with those with elevated ALT levels. In patients with normal ALT levels,
virological non-response to therapy results in new elevations in serum ALT levels in a small minority only.
I
nfection with the hepatitis C virus (HCV) affects an
estimated 2.7 million people in the USA.1 Clinical
manifestations and spectrum of disease in those with
chronic infections are broad and diverse. Approximately 20%
of those with chronic infection progress to life threatening
complications of hepatitis C, such as cirrhosis, liver failure, or
hepatocellular carcinoma.2 3 The remainder of patients
manifest varying degrees of symptoms, viraemia, abnormal-
ities in serum aminotransaminase levels, and histological
activity on liver biopsy.
Before the identification of HCV, the diagnosis of non-A,
non-B hepatitis was based on documentation of persistently
elevated serum alanine aminotransaminase (ALT) values.4 It
was only after the widespread use of molecular based assays
for HCV RNA that it became apparent that viraemia was
frequent among individuals with persistently normal ALT. It
has been estimated that 30% of patients with chronic
hepatitis C have persistently normal ALT.5 The natural history
of these patients is still uncertain. Histological examination
of the liver has shown mild to moderate chronic hepatitis in
most cases,6–15 and cirrhosis in some,6 14 15 thus indicating that
the presence of bridging fibrosis, or even cirrhosis, cannot be
ruled out in patients with persistently normal ALT levels and
detectable HCV RNA.
A major concern regarding the treatment of patients with
normal ALT levels was the finding that a large proportion of
patients (58%) had elevated ALT levels following treat-
ment,5 16 raising the possibility that treatment may result in
actual worsening of disease in those who failed to achieve
viral clearance. All of these studies however involved the use
of interferon a monotherapy. It is uncertain if treatment with
combination interferon and ribavirin in patients with
persistently normal ALT levels results in rates of viral
clearance comparable with those with elevated ALT.
Therefore, we have undertaken a retrospective study to
determine the outcome of interferon a and ribavirin
combination therapy in patients with normal ALT levels
compared with those with elevated ALT levels.
PATIENTS AND METHODS
This was a retrospective study on all patients treated with
combination interferon a and ribavirin at the Liver Clinic,
Veterans Affairs Medical Center, San Francisco and the
University of California, San Francisco, USA, between July
1998 and February 2001. All patients fulfilled the following
criteria: (1) positive for anti-HCV by second generation
enzyme linked immunosorbent assay (Ortho Diagnostics
System, Raritan, New Jersey, USA); (2) detectable serum
HCV RNA; (3) hepatitis B surface antigen negative; (4)
absence of antihuman immunodeficiency virus antibodies;
(5) no other chronic liver disease (alcoholic liver disease,
hepatotoxic drugs, autoimmune chronic hepatitis, haemo-
chromatosis); (6) treatment or interferon naı¨ve; and (7)
absence of decompensated liver disease.
Patients were prescribed subcutaneous recombinant inter-
feron a-2b 3 mU (Schering-Plough, Kenilworth, New Jersey,
USA) three times weekly and oral ribavirin 1000 or 1200 mg
daily (1000 mg for those less than 75 kg body weight and
1200 mg for those more than 75 kg) (Schering-Plough) for
48 weeks. Patients were followed up at monthly intervals
while on treatment, every three months during the first year
post treatment, and approximately half yearly thereafter until
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: HCV, hepatitis C virus; ALT, alanine aminotransaminase;
AST, aspartate aminotransaminase; SVR, sustained virological response;
ULN, upper limit of normal; IQR, interquartile range; OR, odds ratio
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the time of analysis (December 2002). During each assess-
ment, complete blood counts and liver biochemistry were
checked. HCV genotype (Inno-LIPA; Innogenetics NV, Ghent,
Belgium) was measured prior to therapy. HCV RNA
(Amplicor HCV Monitor Test 2.0; Roche Diagnostics, New
Jersey, USA) was determined prior to treatment, at week 48,
at week 72, and at the end of follow up in all patients.
A percutaneous liver biopsy was performed prior to therapy
in all patients. Liver biopsies were paraffin embedded and
stained with haematoxylin-eosin safran and Masson’s
trichrome. Histological features were scored for stage of
fibrosis (no fibrosis (F0), portal fibrosis (F1), periportal
fibrosis (F2), septal fibrosis (F3), and cirrhosis (F4)) and
grade of inflammatory activity (portal inflammation only
with no activity (A1), minimal activity (A1), mild activity
(A2), moderate activity (A3), and severe activity (A4)).17
Patients with persistently undetectable HCV RNA six
months after completion of treatment (week 72) were
considered as having achieved a sustained virological
response (SVR).
The primary aim of this study was to compare the response
rates to interferon plus ribavirin combination therapy in
patients with normal ALT levels and elevated ALT levels. The
secondary aim of this study was to document the rate at
which patients with normal ALT levels who were treated
have an apparent worsening of disease, as shown by an
increase in ALT levels. For those with normal ALT levels, an
increase in ALT levels was defined as a rise in ALT by
>1.3 times the upper limit of normal (ULN) on three
different occasions in a six month period.
This study was approved by the local institutional review
board and all patients provided written informed consent for
chart review and data collection.
Statistical analysis
All statistical analyses were performed using the Statistical
Program for Social Sciences (SPSS 10.0 for windows; SPSS
Inc., Chicago, Illinois, USA). The Mann-Whitney U test was
used for continuous variables with skewed distribution and
the x2 with Yates’ correction for continuity, or Fischer’s exact
test for categorical variables. Continuous variables are
expressed as median (interquartile range 25th–75th percen-
tile (IQR)). All statistical analyses were performed on an
intention to treat population. Statistical significance was
defined as p,0.05 (two tailed).
RESULTS
During this period, there were 105 chronic HCV patients
treated with interferon a and ribavirin for 48 weeks, 52
patients (49.5%) in the normal ALT group and 53 patients
(50.5%) in the raised ALT group. Baseline characteristics
of the two groups are shown in table 1, and were com-
parable except for baseline ALT and aspartate aminotransa-
minase (AST) levels (p,0.0001 and p,0.0001, respectively)
(table 1). Patients in the normal ALT group also had a
significantly lower fibrosis stage compared with patients in
the raised ALT group (p = 0.04). No significant difference was
detected in HCV RNA level or infecting genotype between the
two groups (all NS). During this period, there were 108
patients with normal ALT levels who did not receive antiviral
therapy.
Virological response
Eight patients (15.4%) in the normal ALT group required
dose reduction. The reasons for dose reduction were fatigue
(n = 4), anaemia (n = 3), and thrombocytopenia (n = 1). In
the raised ALT group, 10 patients (18.9%) required dose
reduction. The reasons for dose reduction were anaemia
(n = 5), fatigue (n = 3), and thrombocytopenia (n = 2). There
was no significant difference in the number of patients
requiring dose reduction between the two groups (p = 0.64;
odds ratio (OR) 0.78 (95% confidence interval (CI) 0.28–
2.17)).
At the end of treatment, 31 patients (59.6%) in the normal
ALT group and 30 patients (56.6%) in the raised ALT group
had undetectable HCV RNA (p = 0.75; OR 1.13 (95% CI 0.52–
2.46)). SVR was present in 20 patients (38.5%) in the normal
ALT group and in 21 patients (39.6%) in the raised ALT group
(p = 0.90; OR 0.95 (95% CI 0.44–2.09)). In the normal ALT
group, nine patients (27.3%) with genotype 1 had SVR while
11 patients (57.9%) with non-genotype 1 had SVR (p = 0.03;
OR 0.27 (95% CI 0.08–0.90)).
There were no significant differences in baseline character-
istics of patients with SVR and those without SVR in the
normal ALT group (table 2) (all NS).
Treatment was discontinued in six patients (11.5%) from
the normal ALT group. The reasons for discontinuation of
treatment in the normal ALT group were anaemia (n = 3),
depression (n = 2), and thyrotoxicosis (n = 1). Six patients
(11.3%) from the raised ALT group were discontinued from
treatment for anaemia (n = 3), depression (n = 2), and
fatigue despite dose reduction (n = 1). There was no
significant difference in the number of patients requiring
discontinuation of treatment between the two groups
(p = 0.97; OR 1.02 (95% CI 0.31–3.40)). At week 48 and
week 72, no patient in either group defaulted follow up. At
the end of follow up, seven patients (13.5%) in the normal
ALT group defaulted follow up while in the raised ALT group,
five patients (9.4%) defaulted follow up (p = 0.56; OR 1.49
(95% CI 0.44–5.05)).
ALT levels in the normal ALT group
Patients were followed up further (end of follow up)
for a median of 29.8 (IQR 20.8–36.2) months in the
normal ALT group and for a median of 26.1 (IQR 17.7–
36.3) months in the raised ALT group (p = 0.20) after
week 72.
Median ALT levels in patients in the normal ALT group
with SVR, those without SVR but with undetectable
HCV RNA at the end of treatment (relapsers), and those
with detectable HCV RNA at the end of treatment and at
six months after completion of treatment (true non-
responders) are shown in table 3 and fig 1. There was
no significant difference in median ALT levels between
relapsers and true non-responders at week 48, week 72, or at
the end of follow up (p = 0.07, p = 0.61, and p = 0.26,
respectively).
When median ALT levels at week 48, week 72, and at the
end of follow up between relapsers and those with SVR were
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Figure 1 Median alanine aminotransaminase (ALT) levels in patients
with a sustained virological response (SVR), in relapsers, and in true
non-responders in the normal ALT group during and after treatment. FU,
median ALT levels at the end of follow up.
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compared, no significant differences were detected (p = 0.54,
p = 0.08, and p = 0.15, respectively). There was also no
significant difference in median ALT levels at week 48, week
72, and at the end of follow up between true non-responders
and those with SVR (p = 0.07, p = 0.09, and p = 0.10,
respectively).
Table 1 Baseline characteristics of the normal ALT group and the raised ALT group
Normal ALT group (n = 52) Raised ALT group (n = 53) p Value
Age (y) 47.5 (43.3–52) 49 (43–51.5) 0.90
Sex (M:F) 46:6 47:6 1.00
Genotype 0.55
1 33 33
2 9 6
3 6 9
Indeterminate 4 5
BMI (kg/m2) 28.2 (25.4–29.2) 25.5 (21.4–31.7) 0.35
ALB (g/l) 4 (3.8–4.2) 4 (3.8–4.1) 0.46
BIL (mg/dl) 0.8 (0.5–0.9) 0.7 (0.6–0.9) 0.60
ALT (U/l) 45 (32.5–53) 132.5 (109–179.8) ,0.0001
AST (U/l) 46 (37–52) 92.5 (73.5–139) ,0.0001
ALP (U/l) 69 (57.3–87.3) 68 (54–87) 0.47
HCV RNA (IU/ml) 420 000 (83 000–.850 000) 530 000 (50 570–.850 000) 0.60
Race 0.16
Caucasian 16 20
African American 5 1
Other 1 4
Decline to answer 30 28
Education 0.63
College 17 18
High school 5 6
Elementary school 0 1
Decline to answer 30 28
Annual income 0.07
.$50 000 1 4
$25 000–$50 000 4 7
$10 000–$25 000 9 2
,$10 000 7 7
Decline to answer 31 33
Risk for infection 0.10
Transfusion 15 26
IV drug abuse 20 14
Unknown 17 13
Stage of fibrosis 0.04
F0–F1 24 14
F2–F3 28 39
Necroinflammatory
grade
0.17
A0–1 11 6
A2–3 41 47
BMI, body mass index; ALB, albumin; BIL, bilirubin; ALT, alanine aminotransaminase; AST, aspartate
aminotransaminase; ALP, alkaline phosphatase; HCV, hepatitis C virus; IV, intravenous.
Values are median (interquartile range 25th–75th percentile) or number.
Table 2 Baseline characteristics of patients with SVR and those without SVR in the normal
ALT group
Patients without SVR (n = 32) Patients with SVR (n = 20) p Value
Age (y) 47.5 (44–53) 47.5 (43–51) 0.90
Sex (M:F) 29:3 17:3 0.66
Genotype 0.03
1 24 9
Non-1 8 11
(2) (4) (5)
(3) (2) (4)
(Indeterminate) (2) (2)
BMI (kg/m2) 27.4 (24.4–29.2) 26.6 (22.4–34.2) 0.24
ALB (g/l) 4 (4–4.2) 3.8 (3.8–4.1) 0.08
BIL (mg/dl) 0.8 (0.6–1.0) 0.7 (0.5–0.8) 0.09
ALT (U/l) 47 (40–53) 50 (41–55) 0.49
AST (U/l) 46 (32–54) 47 (39–51) 0.85
ALP (U/l) 70 (57–90) 67 (57–87) 0.98
HCV RNA (IU/ml) 450 000 (83 000–.850 000) 420 000 (75 020–.850 000) 0.94
Stage of fibrosis 0.66
F0–F1 14 10
F2–F3 18 10
SVR, sustained virological response; BMI, body mass index; ALB, albumin; BIL, bilirubin; ALT, alanine
aminotransaminase; AST, aspartate aminotransaminase; ALP, alkaline phosphatase; HCV, hepatitis C virus.
Values are median (interquartile range 25th–75th percentile) or number.
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At the end of follow up, three patients (9.4%) in the normal
ALT group developed persistent elevation in ALT levels. The
elevation in ALT levels occurred more than six months after
completion of treatment. These three patients were true non-
responders. None of the relapsers developed transient rises in
ALT levels.
DISCUSSION
Van Thiel et al and Rossini et al demonstrated in 1997 that the
virological response to interferon therapy in patients with
normal ALT levels was similar to patients with elevated
ALT.15 18 Gordon et al, in their analysis of the subgroup of
patients with slightly elevated ALT levels (defined as
1–1.3 times the ULN) from a multicentre interferon plus
ribavirin trial, found that the 71 patients in this subgroup
who received the combination had similar response rates to
the 939 patients with elevated ALT levels (defined as
.1.3 times the ULN) (30% v 37%, respectively).19 The
results of these two studies suggest that virological
responses to interferon plus ribavirin are independent of
ALT levels.
In a pilot study by Lee and Sherman on the outcome of
combination interferon plus ribavirin therapy in patients
with normal ALT levels, the SVR achieved in patients with
normal ALT levels was 47%.20 This was similar to the SVR of
36–41% achieved in patients with elevated ALT levels in the
two landmark studies of combination therapy.21 22 However,
Lee and Sherman used an induction regimen in their study,
as at that time it was believed that patients with normal ALT
levels were more resistant to standard treatments compared
with patients with elevated ALT levels.20 Moreover, Lee and
Sherman did not include patients with abnormal ALT levels
for comparison.
The SVR rate of 38.5% achieved in patients with normal
ALT levels was similar to that achieved in patients with
elevated ALT levels. This is comparable with responses in the
current literature,21–24 thus suggesting that patients with
normal ALT levels are not more resistant to combination
therapy than those with elevated ALT levels, and deleterious
effects of treatment were not observed. Since we undertook
this retrospective study, recommendations regarding the
treatment of patients with normal ALT levels have been
liberalised in the National Institute of Health Consensus
Statement 2002 as the natural history of disease in this
population is poorly defined and some may show disease
progression.25 Our data would support the validity of these
new recommendations.
A total of three patients from the normal ALT group
developed persistently raised ALT levels at the end of follow
up. Persistently raised ALT in these three patients may be part
of the natural history of patients with normal ALT levels, as
identified in a study by Persico and colleagues26 and
Martinot-Peignoux and colleagues27 in which 23% and 21%
of their patients with normal ALT levels developed elevated
ALT levels on follow up. If the relative frequency of patients
with normal ALT levels developing persistently raised ALT
levels is indeed approximately 20%, then the finding of 9.4%
in our series is low. Perhaps even in patients with normal ALT
levels, combination interferon plus ribavirin therapy can
decrease the incidence of developing elevated ALT levels in
those without SVR instead of worsening their ALT levels, as
was initially feared.28 Furthermore, there were no significant
differences in median ALT levels at week 48, week 72, or at
the end of follow up between patients with SVR, relapsers,
and true non-responders.
The results of this study must be interpreted with care
because of several limitations. Firstly, there was no rando-
mised control group of patients with normal ALT levels who
did not receive treatment. Secondly, as with all other studies
on patients with normal ALT levels, we do not know
historically whether patients in the normal ALT group had
normal ALT levels before they presented to our clinic or if
they were in a stage of transient although prolonged
biochemical remission before commencement of treatment.
Thirdly, as this was not a prospective study, follow up liver
biopsies to demonstrate whether ALT levels in those without
SVR reflected worsening or improvement in disease were not
available. Fourthly, this retrospective study did not allow us
to calculate the cumulative doses of interferon and ribavirin
or to determine the indication for liver biopsy or treatment of
patients with normal ALT levels. Finally, the possibility of a
type II error cannot be excluded due to the small number of
patients.
In conclusion, this study showed that interferon and
ribavirin combination therapy for chronic hepatitis C in
patients with normal ALT levels caused comparable SVR
rates to those with elevated ALT levels. Combination
therapy did not lead to an increased risk of persistently
increased ALT levels in patients without SVR. Therefore,
patients with normal ALT levels should be evaluated for stage
of liver disease as a treatment option is now available.
However, the majority of patients with normal ALT levels do
not show significant fibrosis and thus do not require
treatment.
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